LRMR vs. VERV, ALT, KALV, TVTX, OCS, STTK, CMPS, ABUS, ANL, and ATXS
Should you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Verve Therapeutics (VERV), Altimmune (ALT), KalVista Pharmaceuticals (KALV), Travere Therapeutics (TVTX), Oculis (OCS), Shattuck Labs (STTK), COMPASS Pathways (CMPS), Arbutus Biopharma (ABUS), Adlai Nortye (ANL), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Larimar Therapeutics (NASDAQ:LRMR) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
Larimar Therapeutics received 10 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 60.87% of users gave Larimar Therapeutics an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.
Larimar Therapeutics presently has a consensus price target of $18.50, suggesting a potential upside of 135.07%. Verve Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 429.70%. Given Verve Therapeutics' higher possible upside, analysts clearly believe Verve Therapeutics is more favorable than Larimar Therapeutics.
Larimar Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 4.3% of Larimar Therapeutics shares are owned by insiders. Comparatively, 21.4% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Larimar Therapeutics has a net margin of 0.00% compared to Verve Therapeutics' net margin of -1,226.51%. Larimar Therapeutics' return on equity of -35.69% beat Verve Therapeutics' return on equity.
Larimar Therapeutics has higher earnings, but lower revenue than Verve Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Verve Therapeutics had 9 more articles in the media than Larimar Therapeutics. MarketBeat recorded 25 mentions for Verve Therapeutics and 16 mentions for Larimar Therapeutics. Verve Therapeutics' average media sentiment score of 0.56 beat Larimar Therapeutics' score of 0.29 indicating that Verve Therapeutics is being referred to more favorably in the news media.
Summary
Verve Therapeutics beats Larimar Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Larimar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Larimar Therapeutics Competitors List
Related Companies and Tools
